Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cider supplement recall

This article was originally published in The Tan Sheet

Executive Summary

Port Washington, N.Y.-based Confidence Inc. has initiated a voluntary recall of one lot of Metaboslim Apple Cider Vinegar brand dietary supplement (lot #3001006) because it contains an undeclared drug ingredient, FDA announces Aug. 17. The agency informed the firm that lab analysis of samples of the supplement found it contained undeclared sibutramine, an FDA-approved drug used as an appetite suppressant for weight loss. The affected lot was primarily sold in Canada. No illnesses or injuries have been reported to date, but the FDA advises the supplement poses a threat because sibutramine is known to "substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients" with a history of heart disorders or stroke, the firm says...

You may also be interested in...



Bayer Confident CureVac COVID Pact Will Be A Success

CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.

EMA Works On Defining Metadata From RWD Sources

As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.

UCB And Microsoft Expand AI Tie-Up Beyond COVID-19

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel